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Background: To assess whether the Multidisciplinary Risk Assessment and Management Program for Patients with
Diabetes Mellitus (RAMP-DM) led to improvements in biomedical outcomes, observed cardiovascular events and
predicted cardiovascular risks after 12-month intervention in the primary care setting.
Methods: A random sample of 1,248 people with diabetes enrolled to RAMP-DM for at least 12 months was
selected and 1,248 people with diabetes under the usual primary care were matched by age, sex, and HbA1c level
at baseline as the usual care group. Biomedical and cardiovascular outcomes were measured at baseline and at
12-month after the enrollment. Difference-in-differences approach was employed to measure the effect of
RAMP-DM on the changes in biomedical outcomes, proportion of subjects reaching treatment targets, observed
and predicted cardiovascular risks.
Results: Compared to the usual care group, RAMP-DM group had lower cardiovascular events incidence (1.21% vs
2.89%, P = 0.003), and net decrease in HbA1c (−0.20%, P < 0.01), SBP (−3.62 mmHg, P < 0.01) and 10-year cardiovascular
disease (CVD) risks (total CVD risk, −2.06%, P < 0.01; coronary heart disease (CHD) risk, −1.43%, P < 0.01; stroke risk,
−0.71%, P < 0.01). The RAMP-DM subjects witnessed significant rises in the proportion of reaching treatment targets of
HbA1c, and SBP/DBP. After adjusting for confounding variables, the significance remained for HbA1c, predicted CHD
and stroke risks.
Conclusions: The RAMP-DM resulted in greater improvements in HbA1c and reduction in observed and predicted
cardiovascular risks at 12 months follow-up, which indicated a risk-stratification multidisciplinary intervention was an
effective strategy for managing Chinese people with diabetes in the primary care setting.
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Diabetes mellitus (DM) has become one of the major
disease burdens in the world. It was estimated that by
2013, there were at least 382 million people with dia-
betes all over the world [1], and a 55% increase is antici-
pated by 2035 [2]. In Hong Kong, the prevalence of
diagnosed diabetes reached 5% in the whole population
and 20% in those aged above 65 years old. Diabetes is
the leading cause of coronary heart disease, stroke, end
stage renal disease, blindness and amputation [3,4]. Early
screening of the risk factors or precursory symptoms of
diabetic complications is crucial, so early treatment can
be given to prevent complications and mortalities. Many
international guidelines have started to emphasis the
comprehensive care for people with diabetes, which
takes into account the integrated management of micro-
vascular and macrovascular risk rather than only focus-
ing on glycemic control [5-7].
Given the large number of people with diabetes and
the huge disease burden, risk stratification based man-
agement strategy is appealing, so that resources can be
allocated accordingly. Personalized treatment goals in
clinical measurements and lifestyle modifications based
on risk stratification are highly recommended by current
guidelines [6-8]. Personalized diabetology is advocated
by researchers as the potential solution to deal with the
uncertainty in treatment and translate the evidence from
randomized control trials (RCTs) to the real-world.
However, studies on the effects of personalized treat-
ment are sparse [9].
The Chronic Care Model in primary care developed
by Dr. Wagner provided a multidimensional solution to
achieving optimal primary care for patients with chronic
diseases [10]. Among the six components identified in
this model, four are usually explicitly addressed in
chronic care management, which are delivery system re-
design, decision support, clinical information system and
self-management support. A systematic review found
that to achieve positive outcomes, at least two of these
components were included in interventions, and positive
outcomes were found in all five studies containing four
components [11], indicating that multidisciplinary ap-
proach is crucial to improve the control of diabetes.
Previously, a prospective trial of risk stratification and
intervention involving 370 people with diabetes was
completed in the U.S. [12]. Risk stratification was based
on blood pressure, self-monitoring of blood glucose,
microalbuminuria, foot examination and self-reported
complications. Interventions for high-, moderate- and
low-risk groups followed the American Diabetes Associ-
ation Clinical Practice Recommendations. After a 12-
month follow-up, this study found a considerable increase
in the percentage of patients reaching HbA1C < 7% and
blood pressure <130/85 mmHg. The net benefit of theintervention group compared to the control group was
not reported [12]. Although the intervention in this study
involves all the four components of the Chronic Care
Model [10], it was conducted within staff-model primary
care clinics. The generalizability of the study results to
Asian populations is, however, doubtful.
In Asia, researchers of the Joint Asia Diabetes Evalu-
ation Program (JADE) developed a web-based risk strati-
fication and comprehensive care model for people with
diabetes. This model includes a series of risk engines to
stratify patients into different risk groups, and compre-
hensive care protocols recommended by the Inter-
national Diabetes Federation. Doctors can access to this
care model by an electronic portal [13]. This program
addressed the decision support and clinical information
system. It was reported that 3687 patients over seven
Asian countries were enrolled through the electronic
portal during 2007 to 2009, whereas the effectiveness of
this model compared to the usual care is not clear [14].
A complex integrated care program for people with
diabetes and the elderly was piloted in London. The
interventions included risk stratification and a multi-
disciplinary team led by general practitioners or consul-
tants [15]. A comprehensive evaluation approach was
proposed to assess the impact of the program on clinical
outcomes as well as service use [16]. The results of the
evaluation have not reported yet.
Up to date, evidence is lacking about the effectiveness
of risk-stratification and risk-specific management pro-
grams for Chinese people with diabetes in the primary
care setting. This study aimed at evaluating the effective-
ness of a Multidisciplinary Risk Assessment and Man-
agement Program for Patients with Diabetes Mellitus
(RAMP-DM) at 12 months follow-up in terms of bio-
medical outcomes, observed cardiovascular events and
predicted long-term cardiovascular risks in the primary
care setting. This was the first study to provide impera-
tive translational evidence of risk-stratification and risk-
specific management for diabetes in the real world pri-
mary care setting.
Methods
Study design
We conducted a longitudinal comparative study to com-
pare the changes of biomedical measurements, observed
cardiovascular events and cardiovascular risks at 12 months
follow-up using a difference-in-differences approach be-
tween the RAMP-DM group and the usual care group.
Setting of RAMP-DM
The RAMP-DM is a territory-wide program which in-
tends to cover all the people with diabetes under the
care of public General Out-Patient Clinics (GOPCs) in
Hong Kong. GOPCs provide primary care for about
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60% of all the people with diabetes in Hong Kong. From
August 2009 to June 2010, the RAMP-DM was piloted
in four of the seven clusters in Hong Kong. Details of
the RAMP-DM program have been reported elsewhere
[17]. In brief, all people with diabetes under GOPCs care
are eligible to be enrolled in the RAMP-DM. The en-
rolled subjects underwent a series of assessment of risk
factors and potential existing diabetic complications
when they entered the program, which included mea-
surements of basic parameters (body mass index, waist
circumference, blood pressure, etc.), tests of biomedical
parameters (HbA1c, full lipid profile, renal function,
etc.), and examinations of eyes and feet. Based on the re-
sults of these screenings and history of previous compli-
cations, RAMP-DM participants were stratified into
‘very high’, ‘high’, ‘medium’ and ‘low’ risk groups according
to the JADE classification [14]. For RAMP-DM participants
with different risk stratifications, different management
strategies were provided by a team of multidisciplinary
healthcare professionals, which includes associate con-
sultants in family medicine, GOPCs doctors, advanced
practice nurses, registered nurses, and allied health profes-
sionals (namely optometrist, dietitian, podiatrist and
physiotherapist). Enrolled patients were also eligible to be
invited to join the Patient Empowerment Program (PEP),
which is a structured education program delivered by two
non-governmental organizations to enhance patients’
knowledge and skill on diabetes self-care management. In
summary, the interventions for RAMP-DM participants
included nurse assessment (including risk stratification),
and would be arranged in addition to care from GOPCs
doctors, to have nurse intervention, associate consultant
intervention, allied-health professional intervention and
PEP according to risk levels and need.
Patients under usual care, on the other hand, will be
continuously managed solely by GOPCs doctors without
risk assessment and stratification. These patients could
still be referred to allied health professionals and PEP at
their doctors’ discretion.
Subjects
To detect a 5% between group difference in the propor-
tion of achieving the clinical treatment target (HbA1c
<7%), with 80% power and 95% confidence interval, 1,248
subjects were needed in each group. A sample of 1,248
RAMP-DM participants (312 from each of the 4 clusters)
was randomly selected out of 18,492 subjects, who were
enrolled in RAMP-DM between August 2009 and June
2010. A group of 1,248 people with diabetes who attended
GOPC but were not enrolled in RAMP-DM during this
period were matched by age, sex and HbA1c level as a
control group. The baseline dates for RAMP-DM partici-
pants are the dates when they received nurse assessment.For usual care group, the baseline date is set as 30 June
2010. The follow-up period for both groups is 12 months
since their respective baseline dates.
The ethics approval for this study was granted by the
Institutional Review Board of The University of Hong
Kong and relevant clusters.
Outcome measures
The primary outcomes of this study were the changes in
HbA1c, observed cardiovascular events and predicted
10-year cardiovascular risks over 12 months follow-up.
The secondary outcomes were changes in blood pres-
sure, lipid profiles and BMI. We assessed the changes in
biomedical outcomes by mean values as well as the pro-
portions of subjects reaching treatment targets in HbA1c
(<7%), blood pressure (<130/80 mmHg) and LDL-C
(<2.6 mmol/L) recommended by Hong Kong local
framework [18]. The 10-year predicted cardiovascular
risks were estimated by the Framingham risk function
for total cardiovascular disease (CVD) risk [19], and the
UKPDS risk engines for coronary heart disease (CHD)
[20] and stroke [21], respectively. Demographic data,
biomedical outcomes, disease history, drug treatment
and RAMP-DM intervention data were extracted from
the population-based health and intervention linked
database (Clinical Management System) owned by Hos-
pital Authority. To avoid the impact of aging on CVD
risks, we applied the age at baseline to calculate the
CVD risks at both baseline and 12 months.
Data analysis
We used the mean and standard deviation to describe
continuous variables and the categorical variables were
summarized by counts and percentages. Paired t-test
was employed to compare the paired differences in bio-
medical measurements and cardiovascular risks between
baseline and 12 months for all subjects. The differences
in proportions of subjects achieving treatment targets
between baseline and 12 months were examined by the
McNemar test. We applied the Chi-square test to inves-
tigate the between group differences in the incidences of
cardiovascular events.
The difference-in-differences approach was used to
test the between group differences in the changes of bio-
medical measurements, cardiovascular risks and target
achievement rates. In other words, we calculated the
within-group changes over 12 months follow-up for out-
comes of interest, and compared the within-group
changes between RAMP-DM and control groups by t-
test in unadjusted analysis.
To adjust for potential confounders, we constructed
three multiple linear regression models to adjust the base-
line parameters and drug treatment. Model 1 adjusted the
baseline parameters only, model 2 adjusted the baseline
Table 1 Baseline characteristics of participants in
RAMP-DM group and usual care group
RAMP-DM
(N = 1072)
Usual care
(N = 1072)
Mean ± SD or n(%) P-valuea
Demographic
Age (year) 64.3 ± 10.9 65.3 ± 11.7 0.056
Male 534 (49.8%) 534 (49.8%) 1.000
Smokers 106 (9.9%) 90 (8.4%) 0.231
Cluster information 0.767
HKEC 268 (25.0%) 278 (25.9%)
KCC 270 (25.2%) 274 (25.6%)
KWC 256 (23.9%) 262 (24.4%)
NTEC 278 (25.9%) 258 (24.1%)
Clinical
T2DM 1064 (99.5%) 1006 (93.8%) <0.001
Duration of DM (year) 7.9 ± 6.2 7.9 ± 6.6 0.759
HbA1c (%) 7.26 ± 1.17 7.13 ± 1.17 0.033
TC(mmol/L) 5.05 ± 0.96 4.87 ± 0.94 <0.001
HDL-C (mmol/L) 1.23 ± 0.34 1.23 ± 0.33 0.830
LDL-C (mmol/L) 3.10 ± 0.80 2.89 ± 0.79 <0.001
Triglycerides (mmol/L) 1.63 ± 1.08 1.56 ± 1.00 0.2495
SBP≤ 140 mmHg 615 (58.7%) 634 (69.3%) <0.001
DBP≤ 80 mmHg 700 (66.8%) 687 (75.1%) <0.001
SBP/DBP≤ 140/80 mmHg 538 (58.8%) 491 (46.9%) <0.001
No(%) reaching treatment target
HbA1c < 7% 467 (50.54%) 384 (54.9%) 0.079
SBP < 130 mmHg 365 (34.8%) 412 (45.0%) <0.001
DBP < 80 mmHg 700 (66.8%) 687 (75.1%) <0.001
SBP/DBP < 130/80 mmHg 323 (30.8%) 381 (41.6%) <0.001
LDL-C < 2.6 mmol/L 154 (27.3%) 132 (39.4%) <0.001
Predicted cardiovascular risk (%)
Framingham 10-year CVD riskb 35.18 ± 20.68 33.32 ± 20.16 0.0882
UKPDS 10-year CHD riskc 23.25 ± 16.29 22.00 ± 15.90 0.177
UKPDS 10-year stroke riskd 14.51 ± 15.21 15.06 ± 15.79 0.6439
aIndependent t-test for continuous variables and Chi square test for
dichotomous variables.
bPredicted by the Framingham cardiovascular risk function.
cPredicted by the UKPDS CHD risk engine.
dPredicted by the UKPDS stroke risk engine.
BMI, body mass index; CVD, cardiovascular disease; CHD, coronary heart
disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM,
diabetes mellitus; HbA1c, glycated hemoglobin; HDL-C, high density lipid
cholesterol; HKE, Hong Kong East Cluster; KCC, Kowloon Central Cluster; KWC,
Kowloon West Cluster; LDL-C, low density lipid cholesterol; NTEC, New Territories
East Cluster; TC, total cholesterol. T2DM, Type 2 diabetes mellitus.
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adjusted the baseline parameters, drugs treatment at both
baseline and 12 months follow-up.
To further investigate the effects of each component of
the RAMP-DM interventions on the changes of biomed-
ical outcomes and cardiovascular risks, we applied multiple
linear regressions adjusting for the baseline parameters,
and drug treatment among RAMP-DM participants.
We used STATA Version 12.0 (StataCorp LP. College
Station, Texas, U.S.) to conduct all the data analyses,
and a P-value less than 0.05 was considered as statisti-
cally significant.
Results
We excluded 80 control subjects with existing CVD at
baseline and 96 control subjects who were enrolled in
RAMP-DM over 12 months follow-up. The same num-
ber of case–control pairs from RAMP group were ex-
cluded as well (including 54 subjects with previous
CVD). The baseline characteristics of RAMP-DM group
and the usual care group are shown in Table 1.
At baseline (Table 1), the proportions of patients
reaching treatment target (HbA1c < 7%) was similar be-
tween RAMP-DM group and usual care group (P =
0.079). RAMP-DM participants had significantly higher
levels in TC (P < 0.001), LDL-C (P < 0.001) and blood
pressure (P < 0.001), resulting in smaller proportions of
patients reaching treatment targets in LDL-C (P < 0.001)
and blood pressure (P < 0.001). The predicted 10-year total
CVD risk by the Framingham risk function, 10-year risks
of CHD and stroke by the UKPDS risk engines were simi-
lar (P = 0.088, P = 0.177 and P = 0.644, respectively).
Drug treatment and RAMP-DM interventions
Table 2 summarizes the drug treatment and RAMP-DM
interventions for included subjects. At baseline, a signifi-
cantly higher proportion in the usual care group were
using insulin (P < 0.001), and this trend continued at
12 months. Among RAMP-DM participants, on average
39.2% and 13.3% subjects received nurse intervention
and associate consultant intervention respectively. Pa-
tients under usual care were also eligible for PEP and al-
lied health professionals consultation, but the proportions
having these interventions were quite small (2.6% and
1.1%, respectively).
Observed cardiovascular events
Table 3 shows the incidences of observed cardiovascular
events over 12 months follow-up. A total of 12 (1.21%)
and 31 (2.89%) CVD events were observed in RAMP-
DM group and control group respectively. Compared to
the control subjects, RAMP-DM participants had signifi-
cantly lower incidences in CHD (−1.49%, P < 0.001) and
total CVD (−1.77%, P = 0.003).Biomedical outcomes
Over 12 months follow-up, RAMP-DM subjects showed
significant improvements in the control of HbA1c
(−0.11%, P < 0.01), lipid profiles (TC, −0.27 mmol/L, P <
0.01; LDL-C, −0.31 mmol/L, P < 0.01, HDL-C,0.04 mmol/
Table 2 Treatment modalities of participants in RAMP-DM group and usual care group at baseline and 12 months
RAMP-DM (N = 1072) Usual care (N = 1072)
n(%) P-valuea
Treatment Modalities at baseline
On oral glucose-lowering drugs 949 (88.5%) 941 (87.8%) 0.593
On insulin 17 (1.59%) 76 (7.1%) <0.001
On anti-hypertensive drugs 835 (77.9%) 818 (76.3%) 0.382
On lipid-lowering drugs 866 (80.8%) 880 (82.1%) 0.437
Treatment Modalities at 12 months
On oral glucose-lowering drugs 967 (90.2%) 949 (88.5%) 0.207
On insulin 63 (5.9%) 115 (10.7%) <0.001
On anti-hypertensive drugs 871 (81.3%) 852 (79.5%) 0.302
On lipid-lowering drugs 935 (87.2%) 949 (88.5%) 0.354
Enrolled in PEP 77 (7.2%) 28 (2.6%) <0.001
Receiving nurse assessment 1072 (100%) – –
Receiving nurse intervention 766 420 (39.2%) – –
Receiving associate consultant intervention 143 (13.3%) – –
Receiving allied health professionals intervention 190 (17.8%) 12 (1.1%) <0.001
aChi square test.
PEP, patient empowerment program.
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(SBP,-4.20 mmHg, P < 0.01; DBP,-2.53 mmHg, P < 0.01)
and BMI (−0.32 kg/m2, P < 0.01) We observed increase in
the proportions of reaching the treatment targets in
HbA1c (4.11%, P < 0.05), LDL-C (17.52%, P < 0.01) and
blood pressure (5.34%, P < 0.01) (Table 4). In the control
group, a significant increase in HbA1c was observed
compared to baseline (0.10%, P < 0.05). Compared to the
control subjects, RAMP-DM participants showed signifi-
cantly larger improvements in HbA1c (−0.20%, P < 0.01),
HDL-C (0.02 mmol/L, P < 0.05) and blood pressure
(SBP,-3.62 mmHg, P < 0.01; DBP,-1.73 mmHg, P < 0.01).
After adjusting for baseline parameters and drug treat-
ment, the differences in the changes of HbA1c and DBP
were still significant (Table 4).
Predicted cardiovascular risks
After 12 months of follow-up, significant decreases in
predicted total CVD risks and CHD risks were observedTable 3 Observed one-year cardiovascular events over
12-month follow-up
RAMP-DM
(N = 1072)
Usual care
(N = 1072)
Between groups
differences
Event n(%) n(%) Estimate P-valuea
CHD 2 (0.19%) 18 (1.68%) −1.49% <0.001
Stroke 10 (0.93%) 13 (1.21%) −0.28% 0.529
Total CVD
(CHD + stroke)
12 (1.21%) 31 (2.89%) −1.77% 0.003
aChi Square test.
CVD, cardiovascular disease; CHD, coronary heart disease.in both RAMP-DM and control groups (Table 4). The
control group failed to achieve improvement in stroke
risk. The unadjusted difference-in-differences of cardio-
vascular risks were significant in total CVD risk (−2.06%,
P < 0.01), as well as the specific CHD (−1.43%, P < 0.01)
and stroke risk (−0.71%, P < 0.05), and these differences
remained significant after adjusting for baseline parame-
ters. After adjusting for baseline parameters and drug
treatments, the RAMP-DM participants still showed lar-
ger reductions in the risks of CHD and stroke predicted
by the UKPDS risk engines.
Impact of individual RAMP-DM intervention on biomedical
outcomes and predicted CVD risks
After observing improvements in biomedical outcomes
and reductions in CVD risks in RAMP-DM participants,
multiple linear regression analyses were conducted to
further investigate the impact of each component of
RAMP-DM interventions on the improvements in clin-
ical outcomes among RAMP-participants. The results
are shown in Table 5. After adjusting for baseline parame-
ters, drug treatment at baseline and 12 months, associate
consultant intervention was associated with decreases in
LDL-C (P < 0.05), triglyceride (P < 0.05) and CHD risk
(P < 0.01). PEP was associated with a decrease in BMI,
but a paradoxical increase in DBP.
Discussion
To the best of our knowledge, this is the first study to
evaluate the effectiveness of a risk-stratification manage-
ment approach involving multidisciplinary interventions
Table 4 Comparison of changes in biomedical outcomes and cardiovascular risks between RAMP-DM group and usual care group at 12 months
Paired difference (12 months – baseline) Unadjusted D-in-D Model 1 Model 2 Model 3
Variables RAMP-DM (N = 1072)
Mean (95% CI)
Usual care (N = 1072)
Mean (95% CI)
Estimate (95% CI) Coefficients (95% CI) Coefficients (95% CI) Coefficients (95% CI)
HbA1c (%) −0.11** (−0.18, −0.04) 0.10* (0.01, 0.17) −0.20** (−0.30,-0.09) −0.14** (−0.23,-0.05) −0.11* (−0.21, −0.02) −0.11* (−0.20,-0.02)
TC (mmol/L) −0.27** (−0.33, −0.21) −0.25** (−0.32, −0.19) −0.02 (−0.10,0.07) −0.07 (−0.15,0.01) −0.07 (−0.15,0.01) −0.06 (−0.12,0.03)
LDL-C (mmol/L) −0.31** (−0.38, −0.24) −0.21** (−0.29, −0.13) −0.10 (−0.21, 0.01) −0.03 (−0.07, 0.12) −0.02 (−0.12, 0.07) −0.02 (−0.08, 0.11)
HDL-C (mmol/L) 0.04** (0.03, 0.05) 0.02* (0.002, 0.03) 0.02* (0.01, 0.04) 0.02 (−0.005, 0.04) 0.02 (−0.004, 0.04) 0.02 (−0.004, 0.04)
Triglyceride (mmol/L) −0.09* (−0.18, −0.01) −0.10** (−0.17, −0.03) 0.02 (−0.14, 0.11) 0.04 (−0.07, 0.16) 0.04 (−0.08, 0.16) 0.04 (−0.08, 0.16)
SBP (mmHg) −4.20** (−5.25, −3.04) −0.58 (−0.65, 1.81) −3.62** (−5.31, −1.93) −0.21 (−1.58, 1.16) −0.32 (−1.70, 1.04) −0.40 (−1.73, 0.93)
DBP (mmHg) −2.53** (−3.18, −1.88) −0.60 (−0.06, 1.26) −1.73** (−2.10, −1.16) −0.89* (−1.66, −0.11) −0.95* (−1.73, −0.18) −0.94* (−1.72, −0.16)
BMI (kg/m2) −0.32** (−0.41, −0.23) −0.21** (−0.33, −0.07) −0.11 (−0.26, 0.04) −0.07 (−0.22, 0.08) −0.06 (−0.21, 0.09) −0.06 (−0.21, 0.09)
Percentage reaching treatment target (%)
HbA1c < 7% 4.11* (0.63, 7.60) −1.29 (−5.32, 2.75) 5.40* (0.25, 10.55) 4.24 (−0.79, 9.27) 3.29 (−1.79, 8.37) 3.16 (−1.93, 8.24)
SBP < 130 mmHg 5.34** (1.67, 9.02) 2.19 (−1.79, 6.16) 3.16 (−2.25, 8.57) 4.08 (−1.00, 9.16) 3.74 (−1.35, 8.83) 3.71 (−1.39, 8.81)
DBP < 80 mmHg 8.87** (5.61, 12.14) 0.98 (−2.24, 4.20) 7.89** (3.42, 12.36) 4.49* (0.34, 8.63) 4.58* (0.40, 8.75) 4.57* (0.39, 8.74)
SBP/DBP < 130/80 mmHg 6.20** (2.63, 9.77) 0.43 (−3.43, 4.31) 5.77* (0.51, 11.02) 0.97 (−3.98, 5.93) 7.25 (−4.25, 5.70) 0.74 (−4.23, 5.73)
LDL-C < 2.6 mmol/L 17.52** (12.80, 22.24) 11.94** (5.53, 18.35) 5.58 (−1.99, 13.15) 0.07 (−7.47, 7.62) 0.17 (−7.40, 7.74) 0.50 (−7.00, 8.00)
Predicted cardiovascular risk (%)
Framingham 10-year CVD riska −3.93** (−4.63, −3.32) −1.87** (−2.70, −1.05) −2.06** (−3.14, −0.98) −1.70** (−2.69, −0.68) −1.67 (−2.52, 0.73) −1.73 (−2.65, 0.75)
UKPDS 10-year CHD riskb −3.00** (−3.54, −2.44) −1.55** (−2.19, −0.92) −1.43** (−2.23, −0.58) −1.20** (−2.00, −0.43) −1.22* (−2.02, −0.45) −1.25* (−2.05, −0.45)
UKPDS 10-year stroke riskc −1.17** (−1.49, −0.85) −0.46 (−0.01, 0.01) −0.71* (−1.28, −0.15) −0.96** (−1.50, −0.49) −1.00** (−1.51, −0.49) −0.77** (−1.30, −0.23)
*P-value < 0.05; **P-value <0.01.
aPredicted by the Framingham cardiovascular risk function.
bPredicted by the UKPDS CHD risk engine.
cPredicted by the UKPDS stroke risk engine.
D-in-D, difference-in-differences; BMI, body mass index; CVD, cardiovascular disease; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; HbA1c, glycated
hemoglobin; HDL-C, high density lipid cholesterol; LDL-C, low density lipid cholesterol; TC, total cholesterol.
Model 1, adjusted for age, sex, smoking status, duration of DM, type of DM, and baseline value of the outcome measure; Model 2, adjusted for age, sex, smoking status, duration of DM, type of DM, baseline value of
the outcome measure, and four types of drugs at baseline; Model 3, adjusted for age, sex, smoking status, duration of DM, type of DM, baseline value of the outcome measure, four types of drugs at baseline and
drugs at 12 months.
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Table 5 The impact of each component of RAMP-DM intervention on the change in biomedical measurements and car-
diovascular risks
Multiple linear regressiond
Advanced Nurse Intervention Associate
consultant
intervention
Allied health
professionals
consultation
PEP
Coefficients (95% CI)
Change in HbA1c (%) −0.01 (−0.12, 0.12) −0.12(−0.34, 0.107) −0.19(−0.40, 0.01) −0.19(−0.42, 0.05)
Change in TC 0.05 (−0.06, 0.16) −0.33 (−0.50, −0.16)** −0.09 (−0.27, 0.09) −0.32 (−0.51, −0.13)**
Change in HDL-C 0.01 (−0.02, 0.04) 0.01 (−0.04, 0.04) −0.03 (−0.08, 0.02) −0.03 (−0.07, 0.02)
Change in LDL-C 0.09 (−0.04, 0.22) −0.26 (−0.46, −0.06)* −0.11 (−0.19, 0.17) −0.22 (−0.45, 0.02)
Change in Triglyceride 0.08 (−0.12, 0.27) −0.40 (−0.71, −0.09)* −0.12 (−0.45, 0.20) −0.26 (−0.61, 0.08)
Change in SBP −0.88 (−2.79, 1.03) 2.18 (−0.70, 5.06) −2.45 (−5.70, 0.81) −1.11 (−4.51, 2.29)
Change in DBP −0.35 (−1.48, 0.77) 0.56 (−1.15, 2.26) −0.72 (−2.62, 1.17) 2.43 (0.42, 4.43)*
Change in BMI −0.01 (−0.20, 0.19) −0.07 (−0.39, 0.22) −0.18 (−0.47, 0.10) −0.28 (−0.60, −0.03)
Change in 10-year CVD riska −0.15 (−1.10, 1.41) −1.35 (−3.28, 0.01) −1.59 (−3.64, 0.45) −1.29 (−3.47, 0.01)
Change in 10-year CHD riskb −0.46 (−1.54, 0.62) −2.77 (−4.54, 1.00)** −1.31 (−3.02, 0.04) −1.72 (−3.81, 0.38)
Change in 10-year stroke riskc −0.04 (−1.02, 0.26) 0.99 (−0.20, 0.01) −0.05 (−1.68, 0.01) −0.02 (−1.30, 0.96)
*P < 0.05; **P < 0.01.
aPredicted by the Framingham cardiovascular risk function.
bPredicted by the UKPDS CHD risk engine.
cPredicted by the UKPDS stroke risk engine.
dAdjusted for confounding variables including age, sex, smoking status, duration of DM, type of DM, baseline value of the outcome measure, drugs at baseline
and drugs at 12 months.
BMI, body mass index; CVD, cardiovascular disease; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus;
HbA1c, glycated hemoglobin; HDL-C, high density lipid cholesterol; LDL-C, low density lipid cholesterol; TC, total cholesterol; PEP, patient empowerment program.
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setting. This study found that the RAMP-DM interven-
tion led to lower incidence of cardiovascular events and
significant improvements in HbA1c and predicted cardio-
vascular risks compared to the usual care. Further investi-
gation of the effects of each RAMP-DM intervention
component found that, after adjusting for potential con-
founders, associate consultant intervention was associated
with improvements in lipid control and predicted CHD
risk, while PEP was related to decreases in BMI.
Compared to the previous study on risk stratification
and intervention in staff-model primary care clinics by
Clark et al. [12], the magnitude of improvement in
HbA1c in our study was smaller. In our study, there was
a 0.2% net decrease of HbA1c in RAMP-DM group,
while Clark’s study showed about 0.35% between group
differences in the changes of HbA1c after 12-month
follow-up. Our subjects were much less severe at base-
line with an average HbA1c of 7.2%, whereas the mean
HbA1c in Clark’s study was above 8.5%. The RAMP-DM
is designed to cover all people with diabetes in the pri-
mary care in Hong Kong; therefore, we randomly se-
lected subjects to assess the effectiveness of RAMP-DM
in general instead of selecting severer cases deliberately.
We observed 5.40% more subjects under RAMP-DM
reaching treatment target (HbA1c < 7.0%), which ad-
dressed the clinical benefits of RAMP-DM.RAMP group had a greater increase in the proportions
of reaching HbA1c < 7%, and SBP/DBP < 130/80 mmHg
compared to usual care group, but after adjusting for the
baseline parameters and drug treatment, the differences
became insignificant, although the results were still favor-
ing RAMP-DM participants. Male sex and no history of
myocardial infarction were found to be associated with
uncontrolled blood pressure [22]. As all of our study sub-
jects were without cardiovascular complications at base-
line and gender was well matched between groups, it was
likely that the baseline parameters and drug treatment af-
fected the outcomes. Drug treatment and duration of dis-
ease were indicators of diabetes severity. Moe et.al found
that compared to people with diabetes and without medi-
cation, these on medication subjects had higher risk of
cardiovascular death [23]. For severer subjects at baseline,
doctors might provide them with more intensive care, no
matter they were enrolled in RAMP-DM or not, leading
to bigger improvement. Also, regression to the mean
might lead to bigger reduction for those with higher base-
line HbA1c and SBP levels. In addition, subjects in control
group were also eligible to be referred to some of the ser-
vices in the RAMP-DM intervention package (allied
health professionals and PEP) if necessary, which might
bias the effects of RAMP-DM towards null.
The RAMP-DM group observed fewer coronary heart
disease and total cardiovascular events compared to the
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ent with the findings of the improvement of HbA1c and
predicted cardiovascular risks in RAMP-DM group. A re-
cent study shows that the increase in HbA1c level is signifi-
cantly associated with the incidence of coronary heart
disease during 6 years follow-up [24]. To validate the asso-
ciation in our study, longer follow-up period is needed.
We employed the Framingham cardiovascular risk
function developed for primary care [19] to assess the
longer term effects in total CVD risk, and applied the
UKPDS risk engines [20,21] to predict the changes in
CHD and stroke risks. Although we found that RAMP-
DM participants showed significantly greater improve-
ment in the total CVD risk, the differences were not
significant after adjusting for drug treatment, while the
differences in CHD and stroke risk predicted by the
UKPDS risk engines remained significant. Our previous
study found that the UKPDS risk engine is more sensi-
tive to detect differences in CHD risk in Chinese people
with diabetes [25], as it was developed for people with
diabetes specifically. Moreover, the previous study
showed that the CHD risk predicted by the UKPDS risk
function showed excellent convergent validity with the
JADE risk function that was developed in Chinese
people with diabetes [25,26]. We could not use the JADE
risk function for the estimation of CVD risk in this study
because many required parameters such as estimated
glomerular filtration rate and urine albumin:creatinine
ratio were missing in many subjects.
Very few studies on DM management measured car-
diovascular risk reduction as an outcome. Most studies
only reported changes in blood pressure and lipid pro-
files in addition to HbA1c. Comprehensive cardiovascu-
lar risk management is getting increasing attention in
diabetes care [5,27]. The RAMP-DM provided personal-
ized risk-stratification based care to people with diabetes
by multidisciplinary health care professionals, which pro-
moted the concept of cardiovascular risk management
and facilitated the optimization of medical resources.
The RAMP-DM addressed four interralated components
of the Chronic Care Model [10], with multidisciplinary
management involving doctors, nurses and allied health
professionals. By exploration on individual intervention
components among RAMP-DM participants, we found
that nurse intervention alone was not associated with any
improvements in biomedical outcomes and cardiovascular
risks.
Previous trials on nurses led interventions resulted in in-
consistent findings in changes of HbA1c. The PEACH study
in the Australia primary care setting delivering telephone
coaching on medication goals by practice nurses failed to
achieve improvement in HbA1c and other relevant biomed-
ical measures [28]. A Spain based standardized language in
nursing care plans [29] and a U.S. based nurse caremanagement also showed no improvements in HbA1c [30].
However, a nurse-led telephone coaching intervention in
the U.S. found significant reductions in HbA1c [31]. Lack-
ing of prescribing rights is likely to limit the role of nurses
in diabetes management, thus affect the benefits of sole
nurses intervention [28].
On the other hand, most multidisciplinary interven-
tions involving at least nurses and physicians found
favoring results on blood glucose control. A multidiscip-
linary intervention for patients with HbA1c higher than
10% in Israel found the intervention group had signifi-
cant decrease in HbA1c after six months. This multidis-
ciplinary team contained diabetologist, the dietician and
the diabetes nurse educator [32]. Positive results were
also found in similar multidisciplinary interventions in
Taiwan [33], the U.S. [34] and France [35]. Most of these
multidisciplinary interventions included diabetic educa-
tion sessions. A symposium convened by American As-
sociation of Diabetes Educators acknowledged that the
most effective education programs occurred within
multidisciplinary teams [36].
The PEP was associated with improvement in BMI,
and had favoring effects on HbA1c, lipid profiles and
SBP. The small number of subjects enrolled in PEP
(7.2%) might be insufficient to detect significant changes.
An independent study on the effectiveness of PEP con-
firmed these favoring results [37]. A RCT was designed
to compare the effects of long-term (2 years) education
program with initial education only in France. The re-
sults are yet to report [38].
There are several limitations of this study. First, since
it is not a RCT, some unknown potential confounders
might affect the results. However, a study found that the
positive effects of interventions in controlled trial set-
tings could not be replicated in real-world primary care
settings [39]. Second, the lipid profiles and blood pres-
sure between the RAMP-DM and usual care groups
were not well matched at baseline, which might affect
the changes over 12 months. Third, the lack of blinding
of clinicians and patients is the inherent limitation of
population based clinical interventions. Fourth, the Fra-
mingham risk function and the UKPDS risk engines
were developed in western population, and the UKPDS
risk engines were developed in subjects with type 2 dia-
betes. We had less than 1% subjects with type 1 diabetes,
which might affect the accuracy of the predicted CHD
and stroke risks. As cardiovascular events need time to
develop, the follow-up period of one year was not long
enough for us to validate the predicted CVD risk with
observed cardiovascular events.
Conclusions
This longitudinal comparative study in a pragmatic pri-
mary care setting found that a multidisciplinary risk
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http://www.cardiab.com/content/13/1/127assessment and management program for people with
diabetes (RAMP-DM) significantly reduced HbA1c, ob-
served CVD events and predicted 10-year cardiovascular
risks over 12 months follow-up. The encouraging results
support the risk stratification and multidisciplinary ap-
proach for the management of diabetic patients. A
further study focusing on the longer term effects of
RAMP-DM in terms of the cardiovascular risk control
and the effects of the frequency of interventions will be
conducted at three years follow-up.
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